Covid-19
Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality.
20 May, 2022 | 11:06h | UTC
Commentary on Twitter
CMV reactivation in #COVID19 critically ill pts:
🦠frequent! >20% in this study
🧪risk depends on severity of illness/occurrence of secondary bacterial infections in #ICU
🏥 prolonged hospital stay & higher mortality but independent association lacking.
📎 https://t.co/N8JVD1GyPQ pic.twitter.com/KYRtLmxtJg— Intensive Care Medicine (@yourICM) May 18, 2022
Opinion | Does Paxlovid help people who have been vaccinated against Covid-19? Show us the data!
19 May, 2022 | 11:07h | UTCDoes Paxlovid help people who have been vaccinated against Covid-19? Show us the data! – STAT
Review: Unexplained post-acute infection syndromes.
19 May, 2022 | 10:58h | UTCUnexplained post-acute infection syndromes – Nature Medicine (if the link is paywalled, try this one)
Commentary on Twitter
A @NatureMedicine tour de force review of the unexplained post-acute infectious syndromes, which includes #LongCovid and many others https://t.co/5RnyY9l0eQ
by @jan_choutka @mhornig @VirusesImmunity pic.twitter.com/dhYeZYnM1U— Eric Topol (@EricTopol) May 18, 2022
Opinion | Bill Gates and the fate of WHO.
19 May, 2022 | 10:56h | UTCOffline: Bill Gates and the fate of WHO – The Lancet
Commentary on Twitter
Offline: Bill Gates and the fate of WHO https://t.co/KKUkdFteUN An oped by @richardhorton1 in @TheLancet which he criticizes both @BillGates & @WHO on their positions to the future of pandemic responses.
— Carlos del Rio (@CarlosdelRio7) May 13, 2022
WHO: 2nd COVID booster for most vulnerable offers benefits.
18 May, 2022 | 11:10h | UTCWHO: 2nd COVID booster for most vulnerable offers benefits – World Health Organization
Scent dogs in detection of COVID-19: triple-blinded randomized trial and operational real-life screening in airport setting.
18 May, 2022 | 11:06h | UTCNews Release: Trained sniffer dogs accurately detect people infected with SARS-CoV-2 – BMJ Newsroom
Commentary: Trained scent dogs detect airline travelers with COVID-19 – CIDRAP
Management of drug interactions with Nirmatrelvir/Ritonavir (Paxlovid).
18 May, 2022 | 11:03h | UTCCommentary: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist
Related:
Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ
Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations
A living WHO guideline on drugs for covid-19 – The BMJ
[Preprint] Effectiveness of a second COVID-19 vaccine booster on all-cause mortality in long-term care facility residents and in the oldest old: a nationwide, retrospective cohort study in Sweden.
18 May, 2022 | 11:05h | UTC
Commentary on Twitter
Confirmation of the 2nd booster protection from death in people age 80+ in Sweden, with a relative vaccine effectiveness 42% (compared w/ the 1st booster)https://t.co/Dq1x00J3Tr pic.twitter.com/fyXJPEcQzC
— Eric Topol (@EricTopol) May 17, 2022
Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings.
17 May, 2022 | 11:05h | UTCRelated:
Cohort Study: Venous or arterial thrombosis and deaths among COVID-19 cases.
17 May, 2022 | 11:02h | UTCInvited Commentary: Risk of arterial and venous thromboses after COVID-19 – The Lancet Infectious Diseases
News Release: COVID-19’s high blood clot risk – University of Oxford
Commentary on Twitter
Clots with Covid: Multi-national report of over 900,000 people indicates propensity of risk for arterial and venous thrombi is in men, with increasing age, and association with fatalities (4-fold in non-hospitalized) https://t.co/muGnDld4Um pic.twitter.com/6bLiHPLInm
— Eric Topol (@EricTopol) May 13, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
RECOVERY Trial: Due to safety concerns, recruitment to higher dose corticosteroids closed for patients with hypoxia on no oxygen or receiving simple oxygen.
17 May, 2022 | 11:04h | UTC
Cohort Study: The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization.
17 May, 2022 | 11:01h | UTCCommentary: Study: Readmission rate for COVID-19 is 11% – CIDRAP
RCT: Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure.
16 May, 2022 | 02:37h | UTCRelated:
RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv
Commentary on Twitter
In this trial, in patients with acute hypoxemic respiratory failure from #COVID19, prone positioning, compared with usual care without prone positioning, did not significantly reduce endotracheal intubation at 30 days. https://t.co/1RyYRtcrYj
— JAMA (@JAMA_current) May 15, 2022
Test-negative, case-control study: Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance.
16 May, 2022 | 02:25h | UTCEditorial: Protecting Children Against Omicron – JAMA
Commentary on Twitter (thread – click for more)
This new JAMA study is worth discussing. It found that, this winter, vax effectiveness in 12-15 yos dropped to 0% after 3-5 months & vaccinated were MORE likely to test+ at month 7. May be confounded (see🧵)
But I don't see this as good reason for boostershttps://t.co/zpkIDdZhnn pic.twitter.com/bxAIDmiR8s— Tracy Høeg, MD, PhD (@TracyBethHoeg) May 14, 2022
Review of thoracic imaging manifestations of COVID-19 and other pathologic Coronaviruses.
13 May, 2022 | 11:36h | UTC
New versions of Omicron are masters of immune evasion.
13 May, 2022 | 11:37h | UTCNew versions of Omicron are masters of immune evasion – Science
Commentary on Twitter
"Based on its immunological profile, it [Omicron & its subvariants] should be called SARS-3"https://t.co/zxV3T2SKIB@gretchenvogel @NewsfromScience
w/ @K_G_Andersen @Tuliodna @linfa_wang pic.twitter.com/ToKDqNGH74— Eric Topol (@EricTopol) May 12, 2022
IDSA updates guidelines on the treatment and management of patients with COVID-19.
13 May, 2022 | 11:35h | UTC
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.
13 May, 2022 | 11:28h | UTCInvited Commentary: A collision of pandemics: HIV and COVID-19 – The Lancet HIV
Commentaries on Twitter
New: Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 by Silvia Bertagnolio and colleagues https://t.co/hAyuWi7fMN #openaccess pic.twitter.com/VmjeYMLPHu
— The Lancet HIV (@TheLancetHIV) May 11, 2022
Clinical features of, and risk factors for, severe or fatal COVID-19 among PLWH admitted to hospital…. https://t.co/KKVKwroy4Z Compared with individuals without HIV, PLWH (96% living in Africa) had 15% ⬆️ odds of severe COVID-19 and were 38% more likely to die in hospital.
— Carlos del Rio (@CarlosdelRio7) May 12, 2022
[Preprint] Long Covid: A systematic review and meta-analysis of 120,970 patients.
13 May, 2022 | 11:30h | UTCLong Covid: A Systematic Review and Meta-Analysis of 120,970 Patients – Preprints with The Lancet
Commentary on Twitter
A systematic #LongCovid review of nearly 200 studies and over 120,000 participants, reinforces the high frequency of symptoms > 6 months, not linked to severity of acute illness, and potential for marked disabilityhttps://t.co/9NYQT1P79G pic.twitter.com/WFzBqghbGI
— Eric Topol (@EricTopol) May 6, 2022
Racial and ethnic disparities in estimated excess mortality from external causes in the US, March to December 2020.
13 May, 2022 | 10:57h | UTCRacial and Ethnic Disparities in Estimated Excess Mortality From External Causes in the US, March to December 2020 – JAMA Internal Medicine (free for a limited period)
Commentary on Twitter
In this study, American Indian or Alaska Native and Black populations experienced high rates or excess deaths from external causes (transportation fatalities homicide, and drug-related deaths) during the early #COIVD19 pandemic. https://t.co/RaatdoaFzI
— JAMA Internal Medicine (@JAMAInternalMed) May 11, 2022
RCT: Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age.
12 May, 2022 | 10:22h | UTC
Commentary on Twitter
Two 50-μg doses of mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age. https://t.co/A5SBK4zK6E pic.twitter.com/7x4JgOwK57
— NEJM (@NEJM) May 11, 2022
Phase 2 RCT: A fourth dose of an mRNA Covid-19 vaccine increases cellular and humoral immunity against SARS-CoV-2.
11 May, 2022 | 11:14h | UTCCommentaries:
What a second booster dose of mRNA COVID-19 vaccines tells us – The Lancet Infectious Diseases
Covid: Fourth-dose jab trial shows good boost – BBC
Commentary on Twitter (thread – click for more)
The results of the @CovBoost fourth dose booster substudy are now online in @TheLancetInfDis
We demonstrated fourth doses of covid vaccines were safe and well tolerated and boost antibody levels above their peak following a third dosehttps://t.co/zGi0iNCAcL
— Alasdair Munro (@apsmunro) May 10, 2022
[Preprint] Modeling transmission of SARS-CoV-2 Omicron in China.
11 May, 2022 | 11:16h | UTCModeling transmission of SARS-CoV-2 Omicron in China – Nature Medicine
Commentary on Twitter
https://twitter.com/EricTopol/status/1524050859054616576
Review: First-generation oral antivirals against SARS-CoV-2.
10 May, 2022 | 11:08h | UTCFirst-generation Oral Antivirals Against SARS-CoV-2 – Clinical Microbiology and Infection
Podcast: Inpatient Covid Management.
10 May, 2022 | 11:03h | UTC#332 Inpatient Covid Management with Dr. Nathan Erdmann. – The Curbsiders